tbuckley/cabot-search huggingface dataset:
Retrospective study of RIT (radiolabelled immunotherapy) with <sup>90</sup>Y-IT (<sup>90</sup>Y-ibritumomab tiuxetan) in relapsing FL (follicular lymphoma) after autologous (BM) bone marrow transplant (ABMT)
Authors: F. Peyrade, C. Triby, B. Slama, X. Fontana, M. Broglia, R. Gressin, H. Naman, C. Hebert, G. Lepeu, P. Bondiau, A. Thyss
Journal: Journal of Clinical Oncology (2008)

3075 Background: 90Y-IT is indicated in relapsing CD20+ FL. The main contraindications are BM involvement >20% and platelets <100,000/mm3. A previous history of ABMT does not allow RIT because of the theoretical BM sequelae resulting from such a treatment. Nevertheless, it seems logical that, if the BM analysis is normal, RIT should be feasible. Methods: We retrospectively reviewed 8 different cases of FL treated with RIT after ABMT in three institutions between October 2005 and March 2007. For each case, we have collected the age, WHO performance status, gender, histopathology, duration between ABMT and rit (TAR), the number of pre-rit chemotherapy lines, bm involvement, blood cell count before RIT, RIT dosage, grade III-IV OMS toxicities, treatment response according Cheson’s criteria and disease free survival. Results: With a median age of 61 years (range, 50–70), all patients were WHO PS <3 and 4 were men. Median number of pre-treatment chemotherapies was 2.8 (range, 2–5). Mean TAR was 3.8 years (range, 1–11). BM biopsy showed no involvement in 5 cases, 10% involvement in 2 and 20% in 1. Platelet count was normal in 5 cases and between 100,000- 150,000/mm3 in 3. Consequently, RIT dosage was lowered to 0.3 mCi/kg in these 3 patients. In one patients with 20% BM involvement a grade IV neutropenia and a very prolonged thrombocytopenia (<20,000/mm3) was observed. The other 7 patients have shown platelet and white blood cell grade III toxicities, with no infections and no blood transfusions required. The median time for complete hematologic recovery was 49.9 days (range, 41- 270). Response assessment has demonstrated 3 complete responses, 3 partial responses, 1 stabilization and 1 progression. With a median follow-up of eleven months, 6 patients are alive, of whom 3 have no evidence of evolving disease. Conclusions: RIT with 90Y-IT at a conventional dosage appears to be feasible in heavily pre-treated CD20+ FL even after ABMT. If no BM dysfunction is detected, it seems possible to use RIT in such patients. Based on these favorable results, a larger retrospective study is required to confirm these data. No significant financial relationships to disclose.
Hematopoietic SIN Lentiviral Micro RNA-Mediated Silencing of BCL11A: Pre-Clinical Evidence for a Sickle Cell Disease Gene-Therapy Trial
Authors: Raffaele Renella, Aleksej Perlov, Chad E Harris, Daniel E. Bauer, Jian Xu, Swaroopa Guda, Michael D. Milsom, Stuart H. Orkin, David A. Williams
Journal: Blood (2012)
TCT-470 Routine Follow Up Coronary Angiography versus Clinical Follow Up Only in Patients with Multi-vessel Disease following Percutaneous Coronary Intervention with Drug-eluting Stents: 3-year Clinical Follow Up Results
Authors: Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Jae Kyeong Byun, Jin oh Na, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2015)
Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with <i>BRAF</i>-mutated advanced cancers and metastatic colorectal cancer.
Authors: David S. Hong, Van Karlyle Morris, Siqing Fu, Michael J. Overman, Sarina Anne Piha-Paul, Bryan K. Kee, Ralph Zinner, David R. Fogelman, Reena Mistry, Imad Shureiqi, Funda Meric-Bernstam, Scott Kopetz
Journal: Journal of Clinical Oncology (2014)

3516 Background: BRAF V600 mutations, present in 5-10% of patients (pts) with metastatic colorectal cancer (mCRC), are considered poor prognostic markers, and <10% of BRAF-mutated mCRC pts respond to a combination of cetuximab (C) and irinotecan (I). Vemurafenib (V), an oral kinase inhibitor to the mutated V600 isoform of BRAF, demonstrated a 5% response rate in a phase I trial with BRAF-mutated mCRC. In vitro data in CRC cell lines has shown that blockade of mutated BRAF by vemurafenib triggers compensatory activation of EGFR. Inhibition of EGFR combined with vemurafenib results in synergistic cytotoxicity in preclinical models, further augmented by irinotecan. The safety and efficacy of the combination in pts with BRAF-mutated advanced malignancies have not been studied. Methods: In this 3+3 phase I study, pts with refractory BRAF-mutated cancer received escalating doses of vemurafenib in combination with cetuximab and irinotecan over a 14-day cycle. Radiographic responses were evaluated every 4 cycles by RECIST 1.1. Adverse events (AEs) were assessed by CTCAE 4.0. Results: Through 1/2014, 10 pts have been enrolled: 7 at dose level 1(DL) (V- 480mg PO BID, C-250 mg/m2 weekly and I- 180mg/m2 every 14 days) and three at DL 2 (increased to V-720mg PO BID). One dose-limiting toxicity was observed at DL1 (grade 3 arthralgia) and resolved with dose reduction. The most common AEs were rash, nausea, and diarrhea. Of the 6 evaluable pts treated at DL 1, 5 had mCRC and 1 had appendiceal adenocarcinoma. Four of the 5 mCRC pts (80%) achieved a partial response. For the 5 mCRC pts, median best response was a reduction of -44% (range, 0% to -70%) with duration of responses of 5, 5+, 8+, 12+, and 14+ cycles. The appendiceal carcinoma pt had disease progression. PK and PD analysis is planned. Conclusions: The combination of vemurafenib with irinotecan and cetuximab seems well tolerated in pts with BRAF-mutated mCRC. Even with a low vemurafenib dose, PRs were seen in 4 of 5 evaluable mCRC pts in the first cohort. Additional pts continue to be enrolled at higher dose levels of vemurafenib. A US cooperative group randomized phase II trial of this combination in BRAF-mutated mCRC (SWOG1406) is planned. Clinical trial information: NCT01787500.
The HER2/neu (erbB2) polymorphism, body mass index, and the risk of endometrial cancer
Authors: J. Lee, S. Tong, K. Lee, J. Kim, Y. Kwon, J. Kim, Y. Kim, J. Yei, Y. Do, S. Kwon
Journal: Journal of Clinical Oncology (2008)

22199 Background: Obesity has been identified as a risk factor for endometrial cancer in epidemiologic studies. The transmembrane receptor with a tyrosine kinase encoded by the HER-2 proto-oncogene is amplified in several types of human carcinomas and provides an attractive therapeutic target. HER-2 genes could be disease susceptibility candidate for endometrial cancer. We evaluated the association between HER-2 genotypes and body mass index (BMI) in a case-control study of endometrial cancer. Methods: Cases and controls for this study were recruited between 2001 and 2005. DNA sample and medical histories were obtained from incident cases of endometrial cancer (n= 126) and population controls (n=302). Genotypes evaluated included HER-2 gene single nucleotide polymorphisms (SNP) in coding region at position -423, -655, -776, -857, -1170, -1177, -1253; and two SNP in intron by SNP-IT assay using SNPstream UHT system. Four of 9 SNPs were polymorphic and had greater than 10% of minor allele frequencies. Statistical adjustment was made for age. Results: We observed a statistically significant association between women who were overweight (BMI >25 kg/m2) and carried at least one variant allele with endometrial cancer risk. Compared with wild-type lean women, the odds ratio (OR) for overweight women variant carriers was about 2–4 fold stronger than that for overweight women who did not carry the variants in each SNPs. Conclusions: In summary, although there is no potential association between HER-2 polymorphisms and endometrial cancer risk, our finding suggest that the HER-2 minor variant alleles is reinforced the risk of endometrial cancer among women with higher BMI than low BMI. Future large studies of the HER-2 polymorphism might clarify this putative gene-epidemiologic interaction. No significant financial relationships to disclose.
TCT-413 Late outcomes for SequentPlease paclitaxel-drug eluting balloons in PCI of de-novo lesions and in-stent restenosis: a single-center, all-comer registry
Authors: Leia Hee, Andrew Terluk, Liza Thomas, Andrew Hopkins, Craig P. Juergens, Sidney Lo, John K. French, Christian J. Mussap
Journal: Journal of the American College of Cardiology (2015)
Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial
Authors: Jésus Gonzalez-Bermejo, Capucine Morélot-Panzini, Marie-Laure Tanguy, Vincent Meininger, Pierre-François Pradat, Timothée Lenglet, Gaëlle Bruneteau, Nadine Le Forestier, Philippe Couratier, Nathalie Guy, Claude Desnuelle, Hélène Prigent, Christophe Perrin, Valérie Attali, Catherine Fargeot, Marie-Cécile Nierat, Catherine Royer, Fabrice Ménégaux, François Salachas, Thomas Similowski
Journal: The Lancet Neurology (2016)
Co-Expression of CD38 with Zap-70 Is Predictive of Treatment Intervention in Patients (pts) with Early Stage Chronic Lymphocytic Leukemia (CLL).
Authors: Jean-Gabriel Coignet, Swaminathan Padmanabhan, Rami Manochakian, Kena C. Miller, Paul Wallace, AnneMarie Block, Asher Alban Chanan-Khan
Journal: Blood (2006)
High-Density Lipoprotein and Atherosclerosis Regression
Authors: Jonathan E. Feig, Bernd Hewing, Jonathan D. Smith, Stanley L. Hazen, Edward A. Fisher
Journal: Circulation Research (2014)

High-density lipoprotein (HDL) particles transport (among other molecules) cholesterol (HDL-C). In epidemiological studies, plasma HDL-C levels have an inverse relationship to the risk of atherosclerotic cardiovascular disease. It has been assumed that this reflects the protective functions of HDL, which include their ability to promote cholesterol efflux. Yet, several recent pharmacological and genetic studies have failed to demonstrate that increased plasma levels of HDL-C resulted in decreased cardiovascular disease risk, giving rise to a controversy regarding whether plasma levels of HDL-C reflect HDL function, or that HDL is even as protective as assumed. The evidence from preclinical and (limited) clinical studies shows that HDL can promote the regression of atherosclerosis when the levels of functional particles are increased from endogenous or exogenous sources. The data show that regression results from a combination of reduced plaque lipid and macrophage contents, as well as from a reduction in its inflammatory state. Although more research will be needed regarding basic mechanisms and to establish that these changes translate clinically to reduced cardiovascular disease events, that HDL can regress plaques suggests that the recent trial failures do not eliminate HDL from consideration as an atheroprotective agent but rather emphasizes the important distinction between HDL function and plasma levels of HDL-C.
Combination Therapy Based on Bortezomib for Newly Diagnosed Multiple Myeloma Patients
Authors: Jingsong He, Li Yang, Dian Jin, Xuanru Lin, Qianqian Yang, Xiaoyan Han, Gaofeng Zheng, Weiyan Zheng, Guoqing Wei, Wenjun Wu, Xiujin Ye, Jimin Shi, Wanzhuo Xie, Jie Zhang, Maofang Lin, He Huang, Zhen Cai
Journal: Blood (2012)
TCT-290 Fractional Flow Reserve Measurement in Non-ST-Elevation Myocardial Infarction: Analysis of the National Inpatient Sample Database
Authors: Nivas Balasubramaniyam, Prakash Harikrishnan, Tanush Gupta, None wilbert S aronow, Chandrasekar Palaniswamy, Robert Timmermans, Hasan Ahmad, Howard A. Cooper, Julio A. Panza
Journal: Journal of the American College of Cardiology (2015)
Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Patients ≥ 60 Years of Age with a Novel Reduced Intensity Conditioning Regimen Incorporating Extracorporeal Photopheresis,
Authors: Furha I. Cossor, Sandy Wong, Kenneth B Miller, Deborah Black, Raymond L. Comenzo, Andreas K. Klein, Alanna Klekar, Valerie Relias, Hedy Smith, Kellie Sprague, Karen M Switkowski, Richard A. Van Etten, Hans-Georg Klingemann
Journal: Blood (2011)
Blood pressure drugs may affect mood disorders
Authors: Jacqui Wise
Journal: BMJ (2016)

Calcium antagonists and β blockers may be associated with an increased risk of mood disorders such as depression, while angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers may decrease the risk, a large cohort study has shown.1

For the study published in Hypertension researchers collected data on 144 066 people from two large Scottish hospitals who were being treated for hypertension with angiotensin antagonists, β blockers, calcium channel blockers, or thiazide diuretics. These people were compared with …
TCT-339 Different Pattern of Neoatherosclerosis for DES versus BMS in Very Late Stent Thrombosis
Authors: Daisuke Nakamura, Guilherme F. Attizzani, Catalin Toma, Tej Sheth, Milana Leygerman, Anas Fares, Emile Mehanna, Setsu Nishino, Anthony Fung, Marco Costa, Hiram Bezerra
Journal: Journal of the American College of Cardiology (2015)
TCT-429 Radial versus Femoral Approach for Coronary Angiography and Intervention in Patients with CABG: Systematic Review and Meta-analysis
Authors: Stefano Rigattieri, Alessandro Sciahbasi, Emmanouil Brilakis, Francesco Burzotta, Sudhir Rathore, Francesco R. Pugliese, Antonis Ziakas, Yu Jie Zhou, Luis Guzman, Richard A. Anderson
Journal: Journal of the American College of Cardiology (2015)
Reply: Is an Earlier and More Intensive Physical Therapy Program Better?
Authors: Amy Nordon-Craft, Dan Malone, Margaret Schenkman, Marc Moss
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

We read with great interest the recent article by Moss and colleagues and appreciated the authors' efforts to determine whether an intensive physical therapy (PT) program improved long-term physical functional performance compared with the standard-of-care PT program (1).However, we would like to point out three concerns regarding this work.First, as the authors mentioned in the discussion, the timing of the first PT session did not appear to be "early."In a landmark study showing the efficacy of early mobilization in mechanically ventilated patients, Schweickert and colleagues started their intervention within 2 days (2).Therapy was initiated for the patients in the Moss and colleagues study at a median of 8 days after intubation, which was nearly equivalent to that of Schweickert and colleagues' control group.However, regardless of the PT program, a higher percentage (z50%) of this study population was discharged for home care than the control group (24%).We would like to have additional information on the intensity of early exercise/mobility before the patients were randomized and outside of the PT sessions.Second, the median duration of mechanical ventilation was a little longer than that of Schweickert and colleagues' study, despite a comparable Acute Physiology and Chronic Health Evaluation II score.This suggests that in the Moss and colleagues' study the presence of other factors made ventilator weaning difficult (1).Particularly, delirium affects not only the duration of mechanical ventilation but also long-term cognitive impairment (3).The provision of information regarding the incidence and effects of delirium or other factors, including nutritional status, might help the readers better understand the results.Third, the short form of the Continuous Scale Physical Functional Performance Test (PFP-10) includes the instrumental activities of daily living (IADL) (4).The present PT program, however, was based on a national survey (5) and did not necessarily include IADL training.Whether a PT program alone could improve the IADL remains uncertain.The PFP-10 score could also be affected by the difference in age between the groups (6).Taken together, the outcome setting on the basis of PFP-10 might not be appropriate for the evaluation of the efficacy of the PT program.Elucidating the aforementioned factors might help in interpreting the results better and in establishing a better intensive PT program.
Association of Nasal Mucosal Vascular Alterations, Gastrointestinal Arteriovenous Malformations, and Bleeding in Patients With Continuous-Flow Left Ventricular Assist Devices
Authors: Snehal R. Patel, Shivank Madan, Omar Saeed, Mohammed Algodi, Anne Luke, Marc Gibber, Daniel J. Goldstein, Ulrich P. Jorde
Journal: JACC Heart Failure (2016)
481TiP Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ non-small cell lung cancer (NSCLC): Randomized, open-label, phase 3 KEYNOTE-042 study
Authors: T. Mok, Y.-L. Wu, S. Sadowski, J. Zhang, R. Rangwala, G. de Lima Lopes
Journal: Annals of Oncology (2015)
GW27-e1235 Maleic acid enalaprilat folic acid and Ogilvy sand analysis of H the curative effect of hypertension
Authors: Li Shujun, Zou Yan Ping, Fang Ri Chang, Li Chu Qian, Zhang Tao, Li Pan Pan, Li Jian Ming, Lin Ke, Ji Zhi Gang
Journal: Journal of the American College of Cardiology (2016)
Anti-CD20 Monoclonal Antibody (rituximab) for Refractory PTLD after Pediatric Solid Organ Transplantation: Multicenter Experience from a Registry and from a Prospective Clinical Trial.
Authors: Steven Webber, William Harmon, Albert Faro, Michael Green, Minnie Sarwal, Robert Hayashi, Charles Canter, Dawn Thomas, Ron Jaffe, Richard Fine
Journal: Blood (2004)
TCT-64 Incidence, Predictors, and Impact of Post-discharge Bleeding Compared to Myocardial Infarction After Percutaneous Coronary Intervention
Authors: Philippe Genereux, Gennaro Giustino, Bernhard Witzenbichler, Giora Weisz, Thomas Stuckey, Michael Rinaldi, Franz-Josef Neumann, D. Christopher Metzger, Timothy D. Henry, David Cox, Peter L. Duffy, Ernest L. Mazzaferri, Mayank Yadav, Ajay J. Kirtane, Claire Litherland, Roxana Mehran, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2015)
The reification objection to bottom-up cognitive ontology revision
Authors: Joseph B. McCaffrey, Edouard Machery
Journal: Behavioral and Brain Sciences (2016)

Anderson (2014) proposes a bottom-up approach to cognitive ontology revision: Neuroscientists should revise their taxonomies of cognitive constructs on the basis of brain activation patterns across many tasks. We argue that such bottom-up proposal is bound to commit a mistake of reification: It treats the abstract mathematical entities uncovered by dimension reduction techniques as if they were real psychological entities.
The effect of cancer awareness month campaigns on internet search volume and incidence of cancer diagnoses.
Authors: Wade T. Swenson, John M. Lindblom, John Reber
Journal: Journal of Clinical Oncology (2013)

e17512 Background: Cancer awareness month campaigns are a health promotion tool used to increase public awareness about a specific cancer, its prevention, and treatment. Cancer awareness month campaigns could be most impactful in promoting awareness of cancers for which established screening guidelines exist. Currently, the United States Preventive Task Force endorses screening the general population for colon, cervical and breast cancers. We aimed to assess the effectiveness of campaigns by identifying internet search volume and monthly cancer diagnoses. Methods: GoogleTrends was utilized to identify the relative monthly volume of search terms from 2004 to 2009 as a proxy for public awareness. Search trends for“breast cancer”, “colon cancer”, and “cervical cancer” were analyzed and an average monthly search volume index (SVI) was determined. Surveillance, Epidemiology and End Result (SEER) data was analyzed during the same time period. These data were compared using Pearson's correlation coefficient and the chi square test for seasonality. The monthly trends were compared to corresponding cancer awareness month campaigns (breast cancer-October, colon cancer-March, cervical cancer-January). Results: Internet search volume was highest for colon cancer and breast cancer in the respective cancer awareness campaign months. The frequencies of breast cancer and colon cancer diagnoseswere not significantly higher in the respective cancer awareness months. Cervical cancer search volume and cancer diagnoses did not correlate with awareness campaign months. Search volume and cancer diagnoses were not well correlated for breast cancer (r=0.089) or cervical cancer (r=0.228); however, they were significantly correlated for colon cancer (r=0.386; p-value=0.0008). Conclusions: Cancer awareness month campaigns appear to raise public awareness as estimated by internet search volume for breast cancer and colon cancer. Cervical cancer awareness month campaigns do not have the same effect. There is no significant correlation between cancer awareness campaign months and cancer diagnosis incidence for either breast cancer or cervical cancer, whereas there is a significant correlation for colon cancer.
TCT-442 Early Coverage of Drug Eluting Stents and Bioresorbable Scaffolds Analysed By Optical Coherence Tomography: Evidence of the Impact of Stent Apposition and Strut Characteristic on the Neointimal Healing Process
Authors: Renick D. Lee, Nicolas Foin, Nicole Soh, Ivy Ang, Winston Shim, Ryo Torii, Philip Wong
Journal: Journal of the American College of Cardiology (2015)
Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota
Authors: Jun Wang, Louise B Thingholm, Jurgita Skiecevičienė, Philipp Rausch, Martin Kummen, Johannes R Hov, Frauke Degenhardt, Femke-Anouska Heinsen, Malte C Rühlemann, Silke Szymczak, Kristian Holm, Tönu Esko, Jun Sun, Mihaela Pricop-Jeckstadt, Samer Al-Dury, Pavol Bohov, Jörn Bethune, Felix Sommer, David Ellinghaus, Rolf K Berge, Matthias Hübenthal, Manja Koch, Karin Schwarz, Gerald Rimbach, Patricia Hübbe, Wei-Hung Pan, Raheleh Sheibani-Tezerji, Robert Häsler, Philipp Rosenstiel, Mauro D'Amato, Katja Cloppenborg-Schmidt, Sven Künzel, Matthias Laudes, Hanns-Ulrich Marschall, Wolfgang Lieb, Ute Nöthlings, Tom H Karlsen, John F Baines, Andre Franke
Journal: Nature Genetics (2016)
Centrosome Aberrations in Bone Marrow Cells From Patients with Myelodysplastic Syndromes Correlate with Chromosomal Instability
Authors: Alice Fabarius, Michelle Giehl, Wiltrud Haass, Verena Nowak, Christiane Schumann, Daniel Nowak, Maximilian Mossner, Torsten J Schulze, Stefan A. Klein, Wolfgang Seifarth, Wolf-Karsten Hofmann, Florian Nolte
Journal: Blood (2012)
GW27-e0655 Head to head comparison of two point-of-care platelet function tests used for assessment of on-clopidogrel platelet reactivity in the Chinese acute myocardial infarction patients underwent percutaneous coronary intervention
Authors: Yi Yao, Jiahui Zhang, Xiaofang Tang, Chen He, Yuanliang Ma, Jingjing XU, Ying Song, Ru Liu, Jinqing Yuan
Journal: Journal of the American College of Cardiology (2016)
TCT-689 Chronic anemia is a strong predictor of long-term outcomes in patients undergoing TAVI (POL-TAVI Registry)
Authors: Wojciech Wojakowski, Andrzej J. Ochala, Marek Jasiński, Adam Witkowski, Banasiak Waldemar, Maciej Lesiak, Stefan Grajek, Dariusz Dudek, Dariusz Jagielak, Marek Grygier, Marian Zembala, Janina Stepinska
Journal: Journal of the American College of Cardiology (2015)
Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma
Authors: Thomas Dejoie, Jill Corre, Helene Caillon, Cyrille Hulin, Aurore Perrot, Denis Caillot, Eileen Boyle, Marie-Lorraine Chretien, Jean Fontan, Karim Belhadj, Sabine Brechignac, Olivier Decaux, Laurent Voillat, Philippe Rodon, Olivier Fitoussi, Carla Araujo, Lotfi Benboubker, Charlotte Fontan, Mourad Tiab, Pascal Godmer, Odile Luycx, Olivier Allangba, Jean-Michel Pignon, Jean-Gabriel Fuzibet, Laurence Legros, Anne Marie Stoppa, Mamoun Dib, Brigitte Pegourie, Frederique Orsini-Piocelle, Lionel Karlin, Bertrand Arnulf, Murielle Roussel, Laurent Garderet, Mohamad Mohty, Nathalie Meuleman, Chantal Doyen, Pascal Lenain, Margaret Macro, Xavier Leleu, Thierry Facon, Philippe Moreau, Michel Attal, Herve Avet-Loiseau
Journal: Blood (2016)